Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
117M
-
Number of holders
-
112
-
Total 13F shares, excl. options
-
62M
-
Shares change
-
+6.68M
-
Total reported value, excl. options
-
$867M
-
Value change
-
+$96.2M
-
Put/Call ratio
-
0.68
-
Number of buys
-
74
-
Number of sells
-
-38
-
Price
-
$14.00
Significant Holders of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) as of Q2 2018
146 filings reported holding CHRS - Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share as of Q2 2018.
Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) has 112 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 62M shares
of 117M outstanding shares and own 52.97% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (7.73M shares), FMR LLC (6.9M shares), Temasek Holdings (Private) Ltd (6.56M shares), BlackRock Inc. (4.14M shares), Kohlberg Kravis Roberts & Co. L.P. (3.06M shares), Sofinnova Ventures Inc (2.89M shares), VANGUARD GROUP INC (2.28M shares), JPMORGAN CHASE & CO (2.23M shares), CITADEL ADVISORS LLC (2.11M shares), and STATE STREET CORP (2.11M shares).
This table shows the top 112 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.